Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACO-SWITCH: Acoramidis in ATTR-CM Patients Previously Treated With Tafamidis
NCT07298044Phase 4Recruiting
- Sponsor
- Bayer
- Start
- Feb 2026
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 4 trial of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Bayer. Started Feb 2026; status: recruiting.
02
Drugs
acoramidis
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT07298044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07298044.